ELAV like RNA binding protein 3Genealiases: HUC · HUCL · PLE21
Q-omics provides the consensus-scored ELAVL3 profile across patient tissues and cancer cell-line models. ELAVL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ELAVL3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ELAVL3 RNA expression shows 13,284 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight ACC, COAD, and SARC as cancer lineages where ELAVL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELAVL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELAVL3 survival associations across molecular data types. ELAVL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELAVL3 RNA expression–survival associations across cancer types. High ELAVL3 expression shows unfavorable associations in ACC, KIRP, LIHC and UCS, but favorable associations in SCLC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ELAVL3 RNA expression.
This table summarizes ELAVL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ELAVL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELAVL3 shows lower tumor expression in COAD, STAD, KIRP and KICH and higher tumor expression in LIHC and BRCA. The COAD box plot shows higher ELAVL3 RNA expression in normal versus tumor tissue (log2 FC = −0.459, t-test p < 0.001).
This table shows molecular features associated with ELAVL3 in patient tissues and cancer cell lines. In patient samples, ELAVL3 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELAVL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
